Induction chemotherapy for bone sarcoma in adults: Correlation of results with erbB-4 expression

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1593-1599

  Merimsky, Ofer ^a   Rollender, Yehuda ^a   Issakov, Josephine ^a   Inbar, Moshe ^a   Flusser, Gideon ^a   Benayahu, Dafna ^a   Meller, Isaac ^a   Bickels, Jacob ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bone sarcoma; erbB 4; Induction chemotherapy; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; RETINOBLASTOMA PROTEIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BIOSYNTHESIS; BONE TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HETEROZYGOSITY LOSS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NECROSIS; PATHOLOGY; PROGNOSIS; SARCOMA; TIME; TREATMENT OUTCOME;

ADULT; AGED; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NECROSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; SARCOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 2142856149     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1593     Document Type: Article

References (31)

1. Bieling P, Rehan N, Winkler P, et al: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14: 848-858, 1996. (Pubitemid 26085530)
2. Saeter G, Elomaa I, Wahlqvist Y, et al: Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 273: 156-160, 1997. (Pubitemid 27085235)
3. French Bone Tumor Study Group: Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. Cancer 61: 1304-1311, 1998.
4. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy. A report from the Children's Cancer Group. J Clin Oncol 15: 79-84, 1997.
5. Bacci G, Picci P, Ferrari S, et al: Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer 71: 1224-1230, 1993. (Pubitemid 23054910)
6. Bacci G, Ferrari S, Sangiorgi L, et al: Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother 6: 204-210, 1994. (Pubitemid 24256130)
7. Arndt CA and Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341: 342-352, 1999.
8. Davis AM, Bell RS and Goodwin PJ: Prognostic factors in osteosarcoma. A critical review. J Clin Oncol 12: 423-431, 1994. (Pubitemid 24056419)
9. Baldini N, Scotlandi K, Barbanti-Brodano G, et al: Expression of p-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 333: 1380-1385, 1995.
10. Feugeas O, Guriec N, Babin-Boilletot A, et al: Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14: 467-472, 1996. (Pubitemid 26051009)
11. Onda M, Matsuda S, Higaki S, et al: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77: 71-78, 1996. (Pubitemid 26002739)
12. Trieb K and Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 33: 11-17, 2001. (Pubitemid 32146463)
13. Dickson RB and Lippman ME: Growth factors in breast cancer. Endocr Rev 16: 559-588, 1995.
14. Hendler F, Shum Siu A, Nanu L and Ozanne B: Overexpression of EGF receptors in squamous tumors is associated with poor survival. J Cell Biochem S12A: 105, 1988.
15. Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene. A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986. (Pubitemid 16095607)
16. Slamon DJ, Godolphin W, Jones L, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
17. Hynes N and Stern D: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994.
18. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18: 2201-2209, 2000. (Pubitemid 30350211)
19. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K and Yamamoto T: Localisation of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6: 955-958, 1986. (Pubitemid 16135959)
20. Bongiomo PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB and Beer DG: Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 107: 590-595, 1994. (Pubitemid 24070881)
21. Srinivasan R, Poulsom R, Hurst HC and Gullick WJ: Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumor types. J Pathol 185: 236-245, 1988.
22. American Joint Committee on Cancer. Cancer staging. 5th edition, Chapter 21, pp143-147, 1997.
23. Huvos A: Bone tumors: diagnosis, treatment and prognosis. WB Saunders, Philadelphia, 1991.
24. Bacci G, Ferrari S, Bertoni F, Picci P, Bacchini P, Longhi A, Donati D, Forni C, Campanacci L and Campanacci M: Histologic response of high-grade non-metastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop 386: 186-196, 2001. (Pubitemid 32391293)
25. Ferguson WS and Goorin AM: Current treatment of osteosarcoma. Cancer Invest 19: 292-315, 2001. (Pubitemid 32374371)
26. Lewis IJ, Weeden S, Machin D, Stark D and Craft AW: Received dose and dose-intensity of chemotherapy and outcome in non-metastatic extremity osteosarcoma. J Clin Oncol 18: 4028-4037, 2000. (Pubitemid 32038394)
27. Bielack SS, Kempf-Bielack B, Delling G, Exner UG, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H and Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002. (Pubitemid 34111386)
28. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A and Bacci G: Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 12: 1145-1150, 2001. (Pubitemid 32834497)
29. Merimsky O, Issakov J, Bickels J, Rollender Y, Flusser G, Soyfer V, Schwartz I, Inbar M and Meller I: ErbB-4 expression in limb soft tissue sarcoma. Correlation with results of neoadjuvant chemotherapy. Eur J Cancer 38: 1335-1342, 2002. (Pubitemid 34686843)
30. Merimsky O, Staroselsky A, Inbar M, Schwartz Y, Wigler N, Mann A, Marmor S and Greif J: Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small cell lung cancer. Ann Oncol 12: 1127-1131, 2001. (Pubitemid 32834494)
31. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17: 2781-2788, 1999. (Pubitemid 29415235)